Presentations & Peer Reviewed Articles 2017-10-11T01:02:20+00:00

Presentations and Peer Reviewed Articles

Presentations at Scientific Meetings

Presented at NASH Biomarker Conference in Wash DC May 2017
Principals of Kinetic Measures of Liver Function:   Focus on the HepQuant SHUNT Test

Presented at the AASLD ETC on NAFLD in Washington DC in March 2017
Decreased Hepatic Reserve Determines the Risk of Varices in NASH Patients and in Chronic HCV Patients

Presented at NASH-TAG in Park City Utah in January 2017

  • Diagnosing NASH Patients and Their Risk of Varices and Decompensation by a Global Measure of Liver Function, the HepQuant®-SHUNT Test
  • A Disease Severity Index (DSI) from the HepQuant®-SHUNT Test is Reproducible and Quantifies Hepatic Impairment in Patients with Non-Alcoholic SteatoHepatitis (NASH), Chronic Hepatitis C (CHC), and Primary Sclerosing Cholangitis (PSC)

Presented at the AASLD Liver Meeting in Boston in November 2016
Diagnosing NASH and Assessing NASH Disease Severity by a Global Measure of Liver Function, the HepQuant® (HQ)-SHUNT Test.  Steve M. Helmke, John D. Marr, Michael W. Cookson, Jennifer DeSanto, Shannon Lauriski, James F. Trotter, Gregory T. Everson. Hepatology 2016; 64:584A.

Presented at the ATC in Boston in June 2016
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.  Helmke S, O’Leary J, Burton J, Cookson M, Lauriski S, Trotter J, McHutchison J, Everson G. American Journal of Transplantation 2016; 16 (S3): 297.

Presented at the AASLD Liver Meeting in San Francisco in November 2015
A New Simple Quantitative Liver Function Test, HepQuant-STAT, Correlates with all Chronic HCV Ishak Fibrosis Stages, but Outperforms Fibrosis at Predicting the Risk of Future Clinical Outcomes. Steve M. Helmke, Jennifer DeSanto, Shannon Lauriski, Gregory T. Everson. Hepatology 2015; 62:1111A.

Presented at the ID Week 2015 in San Diego in October 2015
The HepQuant-STAT Liver Function Test Predicts the Risk for Future Clinical Outcomes in Chronic HCV Infection and Could Help Prioritize Patients for Antiviral Treatment. Steve M. Helmke, Jennifer DeSanto, Andrea Herman, Shannon Lauriski, Gregory T. Everson. Open Forum Infectious Diseases, Volume 2, Issue suppl_1, 1 December 2015, 1973, https://doi.org/10.1093/ofid/ofv131.178

Presented at the EASL International Liver Congress in Vienna Austria in April 2015
Time Course of Hepatic Improvement using HepQuant (HQ)-SHUNT Function Test During and After Treatment with Ledipasvir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplant. James Burton, Jacqueline G. O’Leary, Steve Helmke, Andrea Herman, Michael Cookson, Shannon Lauriski, James F. Trotter, Jill Denning, Phillip Pang, John McHutchison, Gregory T. Everson. Journal of Hepatology 2015 62; (S2) S640-S641.

Presented at the AASLD Industry Colloquium in Durham NC in March 2015
HepQuant-STAT and -SHUNT: New Tools for Clinical Trial Patient Selection and Quantification of Liver Function Improvement

Presented at the AASLD Liver Meeting in Washington DC in November 2014
Early Improvement in the HepQuant® (HQ)-SHUNT Function Test during Treatment with Ledipasvir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation. Jacqueline G. O’Leary, James Burton, Steve Helmke, Andrea Herman, Michael Cookson, Shannon Lauriski, James F. Trotter, Jill Denning, Phillip Pang, John McHutchison, Gregory T. Everson. Hepatology 2015; 60:1134A.

Presented at the AASLD Emerging Trends Conference on Antifibrotic Drug Trials: Strategies and Endpoints in Chicago in June 2014.
Quantifying Liver Function to Assess Effectiveness of Anti-Fibrotic Treatment.  Gregory T. Everson.

Presented at the AASLD Liver Meeting in Washington DC in November 2013
Dual Cholate Liver Function Testing is Better than Fibrosis Stage at Identifying Chronic HCV Patients with Medium/Large Varices and Predicting Future Clinical Outcomes.  Steve M. Helmke, Jennifer DeSanto, Andrea Herman, Asmeen Bhatt, Shannon Lauriski , Gregory T. Everson.  Hepatology 2013; 58:1000A.

Presented at the AASLD-FDA Workshop:  Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease (NAFLD) in Silver Spring in September 2013
Quantitative liver function tests (QLFTs) and their utility to assess liver related outcomes.  Gregory T Everson.

Presented at the AASLD Single Topic Conference on Portal Hypertension in Atlanta in June 2013
A Disease Severity Index Based on Dual Cholate Clearances and Shunt Identifies PSC Patients at Risk of Varices and Variceal Hemorrhage.  Steve M. Helmke, Ariana Wallack, Halley Isberg, Asmeen Bhat, Michael Cookson, Shannon Lauriski , Gregory T. Everson.

Presented at the International Liver Transplantation Society meeting in Sydney in June 2013
Cholate Testing is Superior to MELD in Assessing Disease Severity in Patients with Primary Sclerosing Cholangitis.  Helmke SM, Wallack A, Herman A, Isberg H, Brocato M, Bhatt A, Lauriski S, Everson GT.  Liver Transplantation 2013; 19:S97-98.

Serial Cholate Testing is Better than ∆MELD in Assessing Disease Progression in Waiting List Patients with Primary Sclerosing Cholangitis.  Helmke SM, Wallack A, Herman A, Isberg H, Brocato M, Bhatt A, Lauriski S, Everson GT.  Liver Transplantation 2013; 19:S294.

Presented at the American Transplant Congress in Seattle in May 2013
A Disease Severity Index Based on Dual Cholate Clearances and Shunt Identifies PSC Patients at Risk for Clinical Complications.  Helmke SM, Wallack A, Isberg H, Bhatt A, Cookson M, Lauriski S, Everson GT.  American Journal of Transplantation 2013; 13(S5):513.

Presented as a lecture at the world’s largest GI conference, Digestive Disease Week 2013, in Orlando in May 2013
A Disease Severity Index Based on Dual Cholate Clearances and Shunt Outperforms Biopsy at Predicting Clinical Outcomes in Chronic Hepatitis C.  Helmke SM, Desanto JL, Herman A, Lauriski S, Everson GT.  Gastroenterology 2013; 144(5):S951-952.

Presented at the EASL International Liver Congress in Amsterdam in April 2013
Noninvasive Cholate Testing Predicts Response to Peginterferon/Ribavirin and Measures Functional Improvement after Sustained Virological Response in Chronic Hepatitis C. Helmke SM, Desanto JL, Herman A, Lauriski S, Everson GT.  Journal of Hepatology 2013; 58: S290-291.

SUBMISSIONS to AASLD 2017

  • Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test
  • The Relationships of Portal Hypertension and Portal-systemic Shunting to Portal and Systemic Markers of the Gut Microbiome and Cytokines of Macrophage Activation in Chronic Hepatitis C
  • Liver Functional Assessment by Dual Cholate Testing Is Strongly Correlated with Direct Portal Pressure and Ishak Fibrosis Stage
  • Portal-systemic Shunt Fraction measured by the HepQuant-SHUNT Test Correlates with the Hepatic Venous Pressure Gradient (HVPG)
  • Hepatic functional deterioration after locoregional therapy (LRT) for hepatocellular carcinoma (HCC) detected by the HepQuant® SHUNT test: a pilot study
  • Evaluation of the Liver’s Function and Physiology Using HepQuant SHUNT to Potentially Differentiate Irreversible from Reversible Hepatic Impairment in Patients with Chronic Passive Hepatic Congestion Secondary to Fontan Circulation

SUBMISSION TO ASCO 2018

Deterioration of hepatic function after locoregional therapy (LRT) for hepatocellular carcinoma (HCC) measured by hepatic cholate clearance: a pilot study (Hoteit M, et al.)

Peer-Reviewed Articles

Below are peer-reviewed scientific articles, published in medical journals, that resulted from the QLFT Study of the HALT-C Trial and demonstrate the potential of research prototypes of HepQuant tests.

 Portal-systemic Shunting in Patients with Fibrosis or Cirrhosis due to Chronic Hepatitis C: the Minimal Model for Measuring Cholate Clearances and Shunt.  Alimentary Pharmacology & Therapeutics / 2007 The Authors, Aliment Pharmacol Ther 26, 401–410 /  Journal compilation / 2007 Blackwell Publishing Ltd.
 The Spectrum of Hepatic Functional Impairment in Compensated Chronic Hepatitis C: Results from the HALT-C Trial  Alimentary Pharmacology & Therapeutics / 2008 The Authors / Journal compilation 2008 / Blackwell Publishing Ltd.
  Quantitative Tests of Liver Function Measure Hepatic Improvement after Sustained Virologic Response: Results from the HALT-C Trial  Alimentary Pharmacology & Therapeutics / 2009 The Authors / Journal compilation 2009 / Blackwell Publishing Ltd.

Abstracts from Presentations Made at Scientific Meetings

Below are abstracts from presentations we have made at scientific meetings held around the globe.

Title

Meeting / Date / Abstract#

Slow, Moderate and Rapid Progressors – Three Distinct Categories of Patients with Primary Sclerosing Cholangitis Detected by Functional Assessment Using Cholate Testing  Hepatology 2012, 56: 1133A / Abstract #2027
Alteration of the Portal Circulation across the Entire Spectrum of Fibrosis in Patients with Chronic Hepatitis C as Measured by Dual Cholate Clearances  Hepatology 2012, 56: 678A / Abstract #1005
Non-invasive Measurement of the Portal Circulation Using Cholates Quantifies Disease Severity in Waiting List Patients with Primary Sclerosing Cholangitis Liver Transplantation 2012, 18: S233 / Abstract #LB65
Non-invasive Measurement of the Portal Circulation Using Cholates Quantifies Disease Severity in Primary Sclerosing Cholangitis  Gastroenterology 2012, 142: S911 / Abstract #375
Significant Alteration of the Portal Circulation in Over Half of the Chronic HCV Patients with Ishak Fibrosis Stage F0-F2 Hepatology 2011, 54: 1328A / Abstract #2063
Hepatic Impairment Measured by Quantitative Tests of Liver Function (QLFTs) Predicts Clinical Outcome in Patients with Advanced Fibrosis: Results from the HALT-C Trial (AASLD 2009)  #1627